Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant-induced myotoxicity

Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This has led...

Descripción completa

Detalles Bibliográficos
Autores principales: Schirris, Tom J. J., Ritschel, Tina, Herma Renkema, G., Willems, Peter H. G. M., Smeitink, Jan A. M., Russel, Frans G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586513/
https://www.ncbi.nlm.nih.gov/pubmed/26416158
http://dx.doi.org/10.1038/srep14533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586513/
https://www.ncbi.nlm.nih.gov/pubmed/26416158
http://dx.doi.org/10.1038/srep14533

Ejemplares similares